Vikas A. Gupta
Expertise in
16
conditions

Dr. Vikas A. Gupta

Neurology | Neurosurgery
1700 S Tamiami Trl, 
Sarasota, FL 
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
1700 S Tamiami Trl, 
Sarasota, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vikas Gupta is a Neurologist and a Neurosurgery provider in Sarasota, Florida. Dr. Gupta is highly rated in 16 conditions, according to our data. His top areas of expertise are Myeloproliferative Neoplasms (MPN), Gallbladder Disease, Stroke, Gallbladder Removal, and Stent Placement. Dr. Gupta is currently accepting new patients.

His clinical research consists of co-authoring 853 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Neurosurgery
Licenses
Neurological Surgery in TX
Hospital Affiliations
Hca Florida Lawnwood Hospital
Languages Spoken
English
Bengali
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
El Paso Health
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

1700 S Tamiami Trl, Sarasota, FL 34239
Other Locations
2000 Health Park Dr, Brentwood, TN 37027

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Enasidenib
Study Phase: Phase 2
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
Enrollment Status: Completed
Publish Date: July 21, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia
A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia
Enrollment Status: Terminated
Publish Date: August 19, 2021
Intervention Type: Drug
Study Phase: Not Applicable
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Enrollment Status: Terminated
Publish Date: March 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
View 8 Less Clinical Trials
Similar Doctors
Expertise in
21
conditions
Dr. Michael A. Vogelbaum
Neurosurgery
Expertise in
21
conditions
Dr. Michael A. Vogelbaum
Neurosurgery

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (51.9 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Vogelbaum is a Neurosurgery provider in Tampa, Florida. Dr. Vogelbaum is highly rated in 21 conditions, according to our data. His top areas of expertise are Glioma, Brain Tumor, Gliomatosis Cerebri, Awake Craniotomy, and Gamma Knife Radiosurgery. Dr. Vogelbaum is currently accepting new patients.

Expertise in
14
conditions
Dr. Robert A. Hauser
Neurology
Expertise in
14
conditions
Dr. Robert A. Hauser
Neurology

University Medical Service Association Inc

13330 Usf Laurel Dr, 
Tampa, FL 
 (52.2 miles away)
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Hauser is a Neurologist in Tampa, Florida. Dr. Hauser has been practicing medicine for over 44 years is highly rated in 14 conditions, according to our data. His top areas of expertise are Parkinson's Disease, Movement Disorders, Drug Induced Dyskinesia, and Tardive Dyskinesia. Dr. Hauser is currently accepting new patients.

Expertise in
25
conditions
Dr. Arnold B. Etame
Neurosurgery
Expertise in
25
conditions
Dr. Arnold B. Etame
Neurosurgery

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (51.9 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arnold Etame is a Neurosurgery provider in Tampa, Florida. Dr. Etame is highly rated in 25 conditions, according to our data. His top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, Awake Craniotomy, and Gamma Knife Radiosurgery. Dr. Etame is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gupta's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile